# CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

> **NCT03559439** · PHASE1 · UNKNOWN · sponsor: **Shanghai Tong Ren Hospital** · enrollment: 9 (estimated)

## Conditions studied

- B-cell Malignancy
- B-cell Lymphoma
- B-Cell Acute Lymphoblastic Leukaemia

## Interventions

- **BIOLOGICAL:** CD19 CAR T

## Key facts

- **NCT ID:** NCT03559439
- **Lead sponsor:** Shanghai Tong Ren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-24
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2020-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03559439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03559439, "CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT03559439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*